AllergyPain ManagementInflammationDentistryNutraceuticalEar Nose & Throat (ENT)RespiratoryConsumerHealth CareMedical
Description
Haleon plc (‘Haleon’) together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
The com…
Analysis
Middle-of-the-road
Haleon plc sits in the middle of our grid: average quality, average price, no obvious signal in either direction.
On valuation, the picture is fair. The owner-earnings multiple stands at 18.2×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 5% a year, against analyst forecasts of 7%. The price, in other words, assumes less than the experts do.
Growth is tepid; the safety picture is stretched. The company scores 12/20 on our value-creation score: creating some value.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Feb 202673
80
2026
All-time high
80
Jun 2026
All-time low
53
Mar 2026
Average rank
69
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
63
—
—
—
Price/Earnings
24
—
—
—
Price/Book
65
—
—
—
Dividend Yield
75
—
—
—
Value (overall)
65
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.